By Finance Pulse in Stock Upgrade —

D. Boral Capital Upgrades Citius Pharmaceuticals to Buy

D. Boral Capital has upgraded Citius Pharmaceuticals (CTXR) stock to Buy from Hold, citing Lymphir's imminent commercialization with a $9 price target.

An aesthetic image showcasing a rising stock chart with Citius Pharmaceuticals' logo subtly integrat
D. Boral Capital Upgrades Citius Pharmaceuticals to Buy

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target, highlighting Lymphir's imminent commercialization.

Source